Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-05082566 + rituximab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PF-05082566 + rituximab is an investigational combination therapy comprising two agents: PF-05082566 (also known as utomilumab), a monoclonal antibody agonist of 4-1BB (CD137), and rituximab, a monoclonal antibody targeting CD20. PF-05082566 activates 4-1BB, a costimulatory receptor on immune cells, enhancing anti-tumor immune responses. Rituximab selectively targets CD20, a surface protein expressed on B-cells, leading to their depletion through mechanisms such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The combination is being assessed in patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma, especially follicular lymphoma and diffuse large B-cell lymphoma. Phase 1 trials evaluate this combination’s safety, tolerability, pharmacokinetics, and establish the recommended phase 2 dose[1][3].
- Other names
- utomilumabPF-05082566 + rituximab
02
Targets
TNFRSF9 (CD137 extracellular domain)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on PF-05082566 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-05082566 + rituximab.